BackSatsuma Pharmaceuticals Overview

Satsuma Pharmaceuticals Receivables

Track Satsuma Pharmaceuticals's receivables ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer average / median

Loading

Satsuma Pharmaceuticals Receivables History

Loading

Satsuma Pharmaceuticals vs. peers: Receivables Comparison

Loading

Satsuma Pharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Satsuma Pharmaceuticals (STSA) FAQ

The latest receivables for STSA is $0 as of March 2023. In the prior-year period, the figure was $0. Investors often review this figure alongside Satsuma Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, STSA's receivables moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Satsuma Pharmaceuticals's operating scale or balance-sheet position.

A receivables figure of $0 for STSA is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting STSA's receivables ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Satsuma Pharmaceuticals's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.